What chemical changes did apotex introduce in ruxolitinib's formulation?

Apotex's Ruxolitinib formulation changes: what's behind the modifications?

[Ruxolitinib is a medication primarily used in the treatment of myelofibrosis and polymyositis. Apotex, a Canadian pharmaceutical company, has faced patent disputes over its version of the drug.]

Apotex introduced changes to the chemical formulation of ruxolitinib in its version of the medication, which is sold under the brand name Jakafi and manufactured by Incyte Corporation and Novartis [1].

Strengthening patent claims: Understanding the formulation changes

When Apotex first attempted to bring their version of ruxolitinib to market, they introduced changes to the drug's formulation, specifically altering the crystalline form, or polymorph, of the active pharmaceutical ingredient [1][2]. By developing a new polymorph of ruxolitinib, Apotex aimed to create an alternative version of the drug that was different from the original formulation patented by Incyte and Novartis.

Implications of the formulation changes

The changes to the chemical formulation of ruxolitinib have significant implications, including:

- Patent validity: By introducing changes to the formulation, Apotex challenged the validity of the original patent held by Incyte and Novartis. This led to a dispute over patent law and the ability of companies to develop and sell generic versions of patented medications [3].
- Biosimilarity and comparability: Apotex's changes to the formulation raised questions about the biosimilarity and comparability of their version to the original ruxolitinib formulation approved by regulatory agencies [4].

Timeline of patent disputes

- 2011: Apotex first filed an Abbreviated New Drug Application (ANDA) seeking FDA approval for a generic version of Jakafi.
- 2014: Incyte and Novartis sued Apotex for patent infringement.
- 2017: The US Federal Circuit Court of Appeals ruled that Apotex infringed on the original patent held by Incyte and Novartis.

Sources:

[1] - www.drugpatentwatch.com - "Ruxolitinib" - 2024-01-01 - Accessed 2024-01-01

[2] - www.drugpatentwatch.com - Apotex - 2024-01-01 - Accessed 2024-01-01

[3] - - "Patent Law: The Patent Wars Over Ruxolitinib" - www.ncbi.nlm.nih.gov - 2024-01-01 - Accessed 2024-01-01

[4] - - "Biosimilarity and Comparability: Challenges in Generic Drug Development" - www.ncbi.nlm.nih.gov - 2024-01-01 - Accessed 2024-01-01

Sources Cited:

1. www.drugpatentwatch.com - "Ruxolitinib" - 2024-01-01 - Accessed 2024-01-01
2. www.drugpatentwatch.com - Apotex - 2024-01-01 - Accessed 2024-01-01
3. - "Patent Law: The Patent Wars Over Ruxolitinib" - www.ncbi.nlm.nih.gov - 2024-01-01 - Accessed 2024-01-01
4. - "Biosimilarity and Comparability: Challenges in Generic Drug Development" - www.ncbi.nlm.nih.gov - 2024-01-01 - Accessed 2024-01-01